Approval status of new indications for Roche’s greffitumab

Glofitamab (Glofitamab) is an immunotherapy drug developed by the Swiss pharmaceutical company Roche Pharma. It is mainly used to treat B-cell malignant tumors such as diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and follicular lymphoma (FL). Recently, new indications for gaffetuzumab have been approved, especially for patients with relapsed or refractory diffuse large B-cell lymphoma who have failed to effectively control the disease after at least two systemic therapies, as well as those with large B-cell lymphoma caused by follicular lymphoma. This approval further expands the scope of application of gaffetuzumab in the field of tumor immunotherapy, bringing new hope to patients who have had poor treatment results for many years.

Grefituzumab, as a bispecific antibody, can simultaneously targetCD20 and CD3, which are located on the surface of B cells and T cells respectively. Through this dual-targeting mechanism, gaffetuzumab can significantly slow down tumor growth or achieve partial remission by connecting tumor cells and immune cells, promoting T cells to attack tumor cells. For patients with relapsed or refractory diffuse large B-cell lymphoma who cannot be effectively controlled by traditional treatments, gaffetuzumab provides an effective treatment alternative.

Approval of this new indication provides additional treatment options for patients who have failed multiple treatments. In clinical studies, gaffetuzumab has shown high efficacy, especially in patients who are unable to undergo hematopoietic stem cell transplantation. In addition to its wide range of indications, the clinical use of gaffetuzumab also requires close attention to possible side effects, such as cytokine release syndrome (CRS) and serious infections, so patients need to be strictly monitored during use.

In general, the expansion of the indications of gaffetuzumab provides a new treatment option for the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, especially bringing a therapeutic breakthrough to patients who have no other treatment options.

Reference materials:https://www.drugs.com/glofitamab.html